|
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Clinical research trials and Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer. Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer  Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
For Condition: bone marrow ablation,Cancer
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with thiotepa, carboplatin, and topotecan followed by bone marrow transplantation in treating patients who have metastatic or progressive rare cancer.
Details: OBJECTIVES: - Improve the long term disease-free survival of patients with rare cancers at high risk for lethal relapse by using myeloablative chemotherapy with thiotepa, carboplatin, and topotecan followed by autologous bone marrow or peripheral blood stem cell rescue. OUTLINE: Autologous bone marrow or peripheral blood stem cells (PBSC) are harvested. Patients receive high-dose thiotepa IV over 3 hours on days -8 to -6, carboplatin IV over 4 hours on days -5 to -3, and topotecan IV over 30 minutes on days -8 to -4. Autologous bone marrow or PBSC are reinfused on day 0. Patients receive filgrastim (G-CSF) IV twice daily beginning on day 1. Patients are followed for 1 year. PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study within 5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /21 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed malignancy of one of the following types: - Wilms' tumor - Liver cancer - Desmoplastic or other small round cell tumor - Nasopharyngeal carcinoma - Fibrosarcoma - Disease that has metastasized and has a cure rate of no greater than 25% with conventional treatment or disease that has progressed after prior chemotherapy, was not then surgically resectable, and has a salvage rate with nonmyeloablative therapies of no greater than 25% required - Maximal benefit from conventional (nonmyeloablative) doses of combination chemotherapy required prior to entry, and it is recommended that patients have received a minimum of one of the following: - 2 courses of high-dose cyclophosphamide (as per protocol MSKCC-90062) - 2 courses of high-dose ifosfamide/etoposide (as in the poor-risk sarcoma protocol MSKCC-90071A) - 1 course of high-dose cyclophosphamide plus 1 course of high-dose ifosfamide/etoposide - Within 3 weeks of initiation of protocol therapy, patients must be: - In CR or good PR OR - Tumor considered "chemosensitive", i.e., a 50% or greater decrease in at least 1 measurable tumor parameter attributable to prior chemotherapy without evidence of progressive disease by any other parameter - Ineligible for other IRB-approved myeloablative regimens - No evidence of current bone marrow involvement on bone marrow aspiration (x4) and biopsy (x2) PATIENT CHARACTERISTICS: Age: - 21 and under Performance status: - Not specified Hematopoietic: - Not specified Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT no greater than 1.5 times ULN - Alkaline phosphatase no greater than 1.5 times ULN - 5'-Nucleotidase no greater than 1.5 times ULN Renal: - Creatinine normal - Creatinine clearance at least 60 mL/min Cardiovascular: - CPK normal - Echocardiogram (or RNCA) normal - EKG normal PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BrianKushner, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Brian Kushner 212-639-6793
Additional Information:
Study ID Numbers: CDR0000078115; MSKCC-92148,NCI-V93-0214
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002515
Other Bone Marrow Ablation Studies:
1. Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
Related Studies:
Other bone marrow ablation Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
|
|
|
|
|
|
|
|
